Retroviral Replicating Vectors in Cancer

Overview

Journal Methods Enzymol

Specialty Biochemistry

Date 2012 Feb 28

PMID 22365776

Citations 15

Authors

Christopher R Logg

Joan M Robbins

Douglas J Jolly

Harry E Gruber

Noriyuki Kasahara

Affiliations

Soon will be listed here.

Abstract

The use of replication-competent viruses for the treatment of cancer is an emerging technology that shows significant promise. Among the various different types of viruses currently being developed as oncolytic agents, retroviral replicating vectors (RRVs) possess unique characteristics that allow highly efficient, non-lytic, and tumor-selective gene transfer. By retaining all of the elements necessary for viral replication, RRVs are capable of transmitting genes via exponential in situ amplification. Their replication-competence also provides a powerful means whereby novel and useful RRV variants can be generated using natural selection. Their stringent requirement for cell division in order to achieve productive infection, and their preferential replication in cells with defective innate immunity, confer a considerable degree of natural specificity for tumors. Furthermore, their ability to integrate stably into the genome of cancer cells, without immediate cytolysis, contributes to long-lasting therapeutic efficacy. Thus, RRVs show much promise as therapeutic agents for cancer and are currently being tested in the clinic. Here we describe experimental methods for their production and quantitation, for adaptive evolution and natural selection to develop novel or improved RRV, and for in vitro and in vivo assessment of the therapeutic efficacy of RRVs carrying prodrug activator genes for treatment of cancer.

Citing Articles

Targeted Suicide Gene Therapy with Retroviral Replicating Vectors for Experimental Canine Cancers.

Sonoda-Fukuda E, Takeuchi Y, Ogawa N, Noguchi S, Takarada T, Kasahara N Int J Mol Sci. 2024; 25(5).

PMID: 38473904 PMC: 10932112. DOI: 10.3390/ijms25052657.

Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma.

Hu M, Liao X, Tao Y, Chen Y Front Immunol. 2023; 14:1285113.

PMID: 38022620 PMC: 10652401. DOI: 10.3389/fimmu.2023.1285113.

Optimal delivery of RNA interference by viral vectors for cancer therapy.

Wong B, Birtch R, Rezaei R, Jamieson T, Crupi M, Diallo J Mol Ther. 2023; 31(11):3127-3145.

PMID: 37735876 PMC: 10638062. DOI: 10.1016/j.ymthe.2023.09.012.

Determinants of Retroviral Integration and Implications for Gene Therapeutic MLV-Based Vectors and for a Cure for HIV-1 Infection.

Pellaers E, Bhat A, Christ F, Debyser Z Viruses. 2023; 15(1).

PMID: 36680071 PMC: 9861059. DOI: 10.3390/v15010032.

Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy.

Qi Z, Long X, Liu J, Cheng P Front Cell Neurosci. 2022; 16:819363.

PMID: 36159398 PMC: 9507431. DOI: 10.3389/fncel.2022.819363.

References

Wang W, Tai C, Kershaw A, Solly S, Klatzmann D, Kasahara N . Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. Neurosurg Focus. 2006; 20(4):E25. PMC: 8295718. DOI: 10.3171/foc.2006.20.4.1. View

Marzio G, Verhoef K, Vink M, Berkhout B . In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies. Proc Natl Acad Sci U S A. 2001; 98(11):6342-7. PMC: 33470. DOI: 10.1073/pnas.111031498. View

Barsov E, Hughes S . Gene transfer into mammalian cells by a Rous sarcoma virus-based retroviral vector with the host range of the amphotropic murine leukemia virus. J Virol. 1996; 70(6):3922-9. PMC: 190270. DOI: 10.1128/JVI.70.6.3922-3929.1996. View

Rainov N, Heidecke V . Clinical development of experimental virus-mediated gene therapy for malignant glioma. Anticancer Agents Med Chem. 2011; 11(8):739-47. DOI: 10.2174/187152011797378724. View

Metzl C, Mischek D, Salmons B, Gunzburg W, Renner M, Portsmouth D . Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors. J Virol. 2006; 80(14):7070-8. PMC: 1489065. DOI: 10.1128/JVI.00020-06. View

Logg C, Tai C, Logg A, Anderson W, Kasahara N . A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum Gene Ther. 2001; 12(8):921-32. PMC: 8184367. DOI: 10.1089/104303401750195881. View

KENDE M, Veronese F, Hill D, Dinowitz M, Kelloff G . Naturally occurring humoral immunity to endogenous xenotropic and amphotropic type-C virus in the mouse. Int J Cancer. 1981; 27(2):235-42. DOI: 10.1002/ijc.2910270217. View

Dalba C, Klatzmann D, Logg C, Kasahara N . Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors. Curr Gene Ther. 2006; 5(6):655-67. DOI: 10.2174/156652305774964659. View

Tai C, Wang W, Lai Y, Logg C, Parker W, Li Y . Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene. Cancer Gene Ther. 2010; 17(9):614-23. PMC: 2938767. DOI: 10.1038/cgt.2010.17. View

10.

Douville R, Hiscott J . The interface between the innate interferon response and expression of host retroviral restriction factors. Cytokine. 2010; 52(1-2):108-15. DOI: 10.1016/j.cyto.2010.04.010. View

11.

Zitvogel L, Tesniere A, Kroemer G . Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006; 6(10):715-27. DOI: 10.1038/nri1936. View

12.

Dent P, Yacoub A, Park M, Sarkar D, Shah K, Curiel D . Searching for a cure: gene therapy for glioblastoma. Cancer Biol Ther. 2008; 7(9):1335-40. DOI: 10.4161/cbt.7.9.6408. View

13.

McCormick F . Cancer gene therapy: fringe or cutting edge?. Nat Rev Cancer. 2002; 1(2):130-41. DOI: 10.1038/35101008. View

14.

Lewis P, Emerman M . Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol. 1994; 68(1):510-6. PMC: 236313. DOI: 10.1128/JVI.68.1.510-516.1994. View

15.

Aragon-Ching J, Zujewski J . CNS metastasis: an old problem in a new guise. Clin Cancer Res. 2007; 13(6):1644-7. DOI: 10.1158/1078-0432.CCR-07-0096. View

16.

Critchley-Thorne R, Simons D, Yan N, Miyahira A, Dirbas F, Johnson D . Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A. 2009; 106(22):9010-5. PMC: 2690021. DOI: 10.1073/pnas.0901329106. View

17.

Flavell R, Sanjabi S, Wrzesinski S, Licona-Limon P . The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol. 2010; 10(8):554-67. PMC: 3885992. DOI: 10.1038/nri2808. View

18.

Stuhlmann H, Jaenisch R, Mulligan R . Construction and properties of replication-competent murine retroviral vectors encoding methotrexate resistance. Mol Cell Biol. 1989; 9(1):100-8. PMC: 362150. DOI: 10.1128/mcb.9.1.100-108.1989. View

19.

Paar M, Schwab S, Rosenfellner D, Salmons B, Gunzburg W, Renner M . Effects of viral strain, transgene position, and target cell type on replication kinetics, genomic stability, and transgene expression of replication-competent murine leukemia virus-based vectors. J Virol. 2007; 81(13):6973-83. PMC: 1933297. DOI: 10.1128/JVI.02470-06. View

20.

Hammill A, Conner J, Cripe T . Oncolytic virotherapy reaches adolescence. Pediatr Blood Cancer. 2010; 55(7):1253-63. DOI: 10.1002/pbc.22724. View